SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
CSTL reported Q3 2026 results. The stock moved -4.9% on the print.
CSTLearnings

Earnings reactions, page 6

Castle Biosciences, Inc. (CSTL) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • Delivered Q3 2026 revenue of $102.9 million, compared to $83.0 million in the third quarter of 2025.
  • Gross margin was 75%, and Adjusted Gross Margin was 77%, compared to 75% and 77%, respectively, for the same periods in 2025.
  • Net loss, which includes non-cash stock-based compensation expense of $11.2 million, was $4.1 million, compared to net loss of $0.5 million for the same period in 2025.
  • Net loss per share and Adjusted Net Loss per Share, Basic and Diluted, was $0.13, compared to net loss per share and Adjusted Net Loss per Share, Basic and Diluted, of $0.02, for the same period in 2025.
  • Adjusted EBITDA was $12.7 million, compared to $9.2 million for the same period in 2025.
  • Net cash provided by operations was $19.7 million, compared to net cash provided by operations of $22.6 million for the same period in 2025.

Guidance

  • Raising full-year 2026 revenue guidance to $385-395 million from $365-375 million
  • Maintains its expectation to achieve positive Adjusted EBITDA for the fourth quarter 2026, the full year 2026 and the full year 2027.

Price and volatility reaction

The stock moved -4.9% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -10.0 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release34.22026-11-05
Close after release32.522026-11-06
Realised move-4.9%close to close
30d ATM IV change-10.0 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →